In the last several decades, there have been significant advances in anticancer therapy.
However, the development of resistance to cancer drugs and the lack of specificity related to …

Cancer drug resistance presents a major barrier to continued successful treatment of
malignancies. Current therapies inhibiting proteins indicated in cancer progression are …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …

Transcription factors (TFs) act as major oncodrivers in many cancers and are frequently
regarded as high-value therapeutic targets. The functionality of TFs relies on direct protein …

Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression.
The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous …

Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of
development, including in abnormal splice variants (AR-SV)-driven advanced stage …

Great strides have been made in the treatment of castration-resistant prostate cancer
(CRPC) with the development of new antiandrogens (enzalutamide) and more potent …

Enzalutamide, a second-generation small-molecule inhibitor of the androgen receptor (AR),
has been approved for patients who failed with androgen deprivation therapy and have …

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer
(CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved …